 |
|
|
| |
DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND
EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Theodore Ruel1, Edward Acosta2, RajendraSingh3, Carmelita Alvero4, Kathleen George5, Stephanie Popson5, Cindy Vavro6, Rohan Hazra7, Andrew Wiznia8, and the P1093 Team. 1University of California, San Francisco, CA; 2University of Alabama at Birmingham, AL;3Glaxosmithkline, King of Prussia, PA; 4Harvard T.H. Chan School of Public Health, Boston, MA;5Family Health International, Durham, NC; 6ViiV Healthcare, Durham, NC; 7Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD;8Albert Einstein College of Medicine, Bronx, NY.
|
| |
|
|
|
|
|
